Veracyte (VCYT) Tops Q1 EPS by 78c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- S&P 500 ends higher as traders shift from AI to healthcare
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
Veracyte, Inc (VCYT) PT Lowered to $54 at Needham & Company
May 11, 2021 6:34 AM EDTNeedham & Company analyst Stephen Unger lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $54.00 (from $88.00) while maintaining a Buy rating.
The analyst commented, "VCYT's 1Q21 revenue was in line with its 4/16/21 preannouncement and EPS adjusted for one-time acquisition expenses beat consensus. Organic... More



